The insulin-like growth factor 2 (Igf2) gene encodes a potent growth factor that is expressed in multiple tissues during embryonic development. Expression at this locus is mediated by genomic imprinting. In the developing endodermal tissues, imprinting of Igf2 is mediated by the interaction of a set of enhancers downstream of the linked H19 gene with a differentially methylated domain (DMD) that lies approximately 2 -4 kb upstream of H19 that has a boundary or insulator function in the hypomethylated state. In the remainder of tissues that express Igf2 and H19, the cis elements that drive their correct expression and imprinting are not well understood. In addition, enhancers driving expression of Igf2 in the choroid plexus and leptomeninges, tissues where the gene is thought not to be imprinted, have not been isolated. Here we show that biallelic (non-imprinted) expression within the choroid plexus is restricted to the epithelium, and we provide evidence that a conserved intergenic region functions as an enhancer for Igf2 both in tissues where the gene is imprinted, and where Igf2 is biallelically expressed. The presence of an enhancer for imprinted tissues in the intergenic region argues for the existence of imprinting controls distinct from the DMD, which may be provided by differential methylation at sites proximal to Igf2.
Introduction
The centrally conserved domain (CCD) was initially characterized by Koide et al. (1994) as a GC-rich, relatively unmethylated region approximately 32 kb upstream of the mouse H19 gene. This region was found to contain DNaseI hypersensitive sites (HSS) as well as a high degree of sequence conservation between mammals, a strong indication that this region is functional. Subsequent analysis (Ainscough et al., 2000) showed that this region can be subdivided into two domains based on comparisons with human sequence (see Fig. 1c , shaded areas). Region 1 shares 86% identity between mouse and human sequences over approximately 100 bp and contains the previously mapped HSS. Region 2 displays 87% identity between the two species over approximately 200 bp. Region 1 has been analyzed in the context of a yeast artificial chromosome (YAC) transgene that contains 130 kb of the mouse genomic region spanning from approximately 5 kb upstream of the first exon of insulin-like growth factor 2 (Igf2) to approximately 35 kb downstream of the H19 gene. With the intact YAC transgene, imprinting is maintained of both an Igf2-LacZ fusion gene and H19, and transgenic mice display expression of both genes in the majority of tissues where Igf2 and H19 are normally expressed (Ainscough et al., 1997) . In transgenic mice where 1 kb of the intergenic region, including Region 1 but not Region 2, was deleted from the same YAC, the maternal allele of LacZ was reactivated in late gestation in a subset of skeletal muscle cells, most notably those of the tongue (Ainscough et al., 2000) . Region 1 therefore contains a maternal allelespecific, tissue-specific silencer that is active in late gestation. The role of Region 2 has not been elucidated, though evidence from transgenic and germline knock out experiments suggests that it may contain the exchange tissue enhancers (Jones et al., 2001; Ward et al., 1997) .
Imprinting of the Igf2 gene in endodermal tissues is thought to be mediated by the interaction of tissue-specific enhancer elements with a differentially methylated domain (DMD) 2 -4 kb upstream of the H19 gene (for relative positions, see Fig. 1 ). On the maternal allele, where the DMD is unmethylated, it functions as a boundary to prevent the access of downstream enhancers to the Igf2 gene. This boundary function is mediated by the protein CTCF (Bell and Felsenfeld, 2000; Hark et al., 2000; Kanduri et al., 2000; Pant et al., 2003; Szabo et al., 2000) . On the paternal allele, methylation of the DMD prevents CTCF binding; therefore, the Igf2 promoters and the downstream enhancers are able to interact. If the DMD provides the sole imprinting element for Igf2, a prediction would be that the enhancers that drive imprinted Igf2 expression would lie on the opposite side of the boundary. Indeed, a region that can drive gene expression in skeletal muscle, where Igf2 is abundantly expressed and imprinted, has recently been mapped as lying approximately 28 -30 kb downstream of the H19 gene, on the predicted side of the boundary (Kaffer et al., 2000) , and is one of many putative enhancers in this region (Davies et al., 2002; Ishihara et al., 2000) . However, the existence of several regions of differential methylation proximal to Igf2 (DMR0, DMR1, DMR2, see Fig. 1 ) that display methylation-dependent, tissue-specific silencer activity (Constancia et al., 2000; Eden et al., 2001; Murrell et al., 2001) argues that the DMD may not directly mediate the imprinting of Igf2 in all tissues.
The CCD lies between the Igf2 gene and the DMD and consequently the CCD should not be affected by the boundary element that prevents the interaction of Igf2 with more distant enhancers. We therefore considered the CCD as a good candidate for driving expression in the tissues where Igf2 is biallelically expressed, the choroid plexus and leptomeninges. To test this hypothesis, we have created transgenic mice that carry the CCD in the context of a (Ainscough et al., 2000) referred to in the text is the 5V 1 kb EcoRI (E) -PstI (P) interval containing Region 1.
LacZ reporter construct. As expected, these mice express the reporter gene in the exchange tissues of the brain. We show that within the choroid plexus endogenous, Igf2 expression is imprinted in the stromal compartment (with the paternal allele active) but non-imprinted in the epithelium (both alleles expressed), and that this is opposite to the pattern of H19 expression (with the maternal allele expressed in the stroma and both alleles silent in epithelium). The CCD was able to drive transgene expression in both stromal and epithelial components of the choroid plexus in a pattern very similar to that of endogenous Igf2 expression. In addition, the CCD was able to reproducibly drive gene expression in further tissues of mesodermal or neural crest origin that are consistent with the known expression pattern of Igf2. The presence of an enhancer for Igf2 proximal to the boundary, in addition to the existence of tissue-specific silencers upstream of the Igf2 gene, suggests that a second mechanism acts to imprint this gene in a subset of tissues.
Methods

Mice
The LacZDMR2 À mice were maintained on an F 1 (CBA Â C57BL6/J) background. To derive embryos for allele-specific expression analysis, male and female mice heterozygous for the LacZDMR2 À mutation were mated with F 1 partners. To distinguish LacZDMR2 À heterozygous embryos from wild-type littermates, yolk sacs were collected and crude lysates were made by heating in 50 mM NaOH at 100jC for 10 min. Lysates were analyzed for the presence of the LacZ reporter by PCR using primers internal to the LacZ gene: 407, 5V ATG AAC GGT CTG GTC TTT GC-3V and 408, 5V ACA TCC AGA GGC ACT TCA CC-3V. The H19 knockout strain, designated H19D3, was previously described, together with methods for distinguishing the wild-type and knockout alleles (Ripoche et al., 1997) .
Transgenesis
The P3-LacZ-CCD construct C (see Fig. 1 ) contained a 3.6 kb coding region of the bacterial h-galactosidase (Lac Z) gene driven from Igf2 promoter 3 (Igf2 P3, as described in Caricasole and Ward, 1993) . The CCD fragment, placed immediately 3V to the LacZ gene, was a 2 kb EcoRI fragment (pA-4, as detailed in Koide et al., 1994) . Cloning steps were performed in the Bluescript II SK+ vector, according to standard techniques (Sambrook et al., 1989) .
Transgenic mouse lines were constructed as follows: Linear construct DNA (1 Ag/ml) was purified from vector sequences and microinjected into one pronucleus of an F1 (C57BL/6JxCBA/Ca) zygote, using standard techniques (Hogan et al., 1986) . Injected embryos were transferred into the oviduct of pseudopregnant MF1 females. Lines were established and maintained by breeding the transgenics with F1 partners.
Founders were identified by PCR of sequences unique to the Igf2 P3-LacZ-CCD transgene (primers Igf2 P3: 5V CTGTGAGAACCTTCCAGCCTTTTC 3V and LacZ: 5V CAAGGCGATTAAGTTGGGTAACGCC 3V) and confirmed by Southern blotting of tail genomic DNA with a probe generated from the transgene construct, according to standard techniques. Copy number was estimated on Southern blots by titrating DNA from hemizygous transgenic animals, with reference to an endogenous band detected using CCD sequences within the transgene probe.
Tissue processing
Embryos and tissues were analyzed for LacZ expression according to Ainscough et al. (2000) , with the following modifications: Samples were incubated in X-Gal or BLU-GAL (Melford Laboratories Ltd) staining solution for 16-24 h, washed with PBS, then fixed overnight in 4% paraformaldehyde in PBS (PFA) and stored in 70% ethanol. Paraformaldehyde fixed material from both LacZ analysis and obtained for in situ hybridization analysis was processed according to standard techniques as described previously (Charalambous et al., 2003) .
Probes and antibodies
The H19 in situ hybridization probe was a 346 bp fragment spanning exons 3 -4 of the mouse H19 cDNA, amplified by PCR using the following primers: 416; 5VAAT GAG TTT CTA GGG AGG GAG G-3V and 417; 5VGGA AAA GTG AAA GAA CAG ACG G-3V, then cloned into the pGEM-T easy vector. Sense and antisense transcripts were obtained for this gene and for Igf2, as described previously (Charalambous et al., 2003) . Transthyretin (TTR) was detected in tissue sections using a rabbit polyclonal antiserum (DAKO) at a dilution of 1:100. Immunohistochemistry and mRNA in situ hybridizations were performed essentially as detailed in Charalambous et al. (2003) .
Results
Generation of P3-LacZ-CCD transgenic mice
To test the CCD function, we created a transgene construct containing the LacZ gene driven by Igf2 promoter 3 (P3), in cis to the CCD (construct C, see Fig. 1 ). Previous experiments have shown that Igf2 P3 alone cannot drive reproducible tissue-specific expression of a reporter gene (Ishihara et al., 2000; Ward et al., 1997) . Construct C (P3-LacZ-CCD) DNA was used to generate five transgenic founder animals, designated Connie, Columbo, Cornelius, Christian, and Clive, all of which were shown by PCR and Southern blotting to transmit the transgene (data not shown). Founder animals were mated to generate an F1 generation of males and females hemizygous for the transgene, and these animals were backcrossed onto stock (CBA/C57BL6) mice to yield the embryos used in this study. Embryos were assayed for the expression of hgalactosidase by an in situ assay at various embryonic and neonatal stages. Within each line, no differences in spatial patterns of gene expression, or obvious differences in the level of gene expression, were observed following the transmission of the transgene from either males or females at any developmental stage examined (not shown). This is consistent with the absence of parental allelespecific methylation or DNaseI hypersensitivity in the CCD (Koide et al., 1994) .
P3-LacZ-CCD reporter transgenes are expressed in tissues where Igf2 is biallelically expressed
Four of five lines demonstrated a detectable level of gene expression from embryonic day 12.5 (e12.5). In the Clive line, the transgene appears to have been silenced by a position effect. As expected, the remaining lines displayed reporter gene expression in the choroid plexus and leptomeninges from their formation at e12.5. Embryos from the Connie line expressed the transgene at very low levels, and not all individuals positive for the transgene demonstrated detectable levels of expression. The Connie line was therefore excluded from further analysis. By e14.5, the Columbo, Cornelius, and Christian lines all expressed the transgene reproducibly in the third, fourth, and lateral ventricle choroid plexus, as well as in the leptomeninges of the brain, and surrounding the spinal cord (Fig. 2a) . Expression of the reporter gene in the choroid plexus and leptomeninges was maintained throughout embryonic development and persisted after birth , consistent with the previously reported endogenous Igf2 expression pattern (Stylianpoulou et al., 1988b) .
The choroid plexus develops from more than one cell population. It is comprised of a stromal stalk that extends into the ventricular cavities of the brain, surrounded by the columnar choroid plexus epithelium. The stroma develops from the same mesenchymal cell population as will form the pia mater of the leptomeninges, some of which may be derived from the neural crest (Catala, 1998; Davson, 1967) . At approximately e10.5 in the mouse, mesenchymal cells overlying the neuroepithelium expand and become highly populated with vasculature. This expansion into the ventricles forms a stromal stalk that retains its ependymal lining. The ependyma is the innermost layer of the neuroepithelium that lines the ventricles of the brain and the spinal cord. Concomitant with the expansion and invagination of the stroma, the ependyma in this region also expands, becoming highly convoluted by e12.5. The morphology of the cells changes from low cuboidal to a high cylindrical epithelium with an apical brush border (Davson, 1967) , the choroid plexus epithelium.
The expression pattern of the reporter gene was compared in detail with that of Igf2 mRNA at mid-gestation. In the fourth ventricle of the brain, both Igf2 and the reporter gene were expressed at high levels in the stromal stalk of the choroid plexus, and in the underlying pia mater and arachnoid mater layers of the leptomeninges (Figs. 2e, f) . At higher magnification (Figs. 2g, h ), a lower level of reporter gene and Igf2 expression can be detected in a scattered cell distribution in the outer epithelial layer of the choroid plexus. Therefore, reporter constructs mirror the expression of Igf2 in both the fine distribution of gene expression within the exchange tissues, and in the maintenance of gene expression in these tissues after birth.
Igf2 is biallelically expressed in the choroid plexus epithelium, but imprinted in the stroma Expression of Igf2 has been previously reported in both the stroma and the choroid plexus epithelium (Stylianpoulou et al., 1988b) . However, whether the gene is biallelically expressed in both compartments has never been resolved (Svensson et al., 1995) . In addition, it is not known whether the expression of the gene is initially parent-of-origin specific in this organ, becoming biallelic as development proceeds, or expressed from both alleles from the onset of development.
To answer these questions, we made use of a previously described allele of Igf2 in which exons 4 -6 (including DMR2) are replaced with a LacZ cassette. This LacZDMR2 À allele faithfully recapitulates the expression of Igf2 (Murrell et al., 2001) . We followed the expression of the reporter in the fourth ventricle choroid plexus of embryos from e9.5 to e14.5 to ask whether Igf2 is expressed from the earliest formation of the organ in both epithelial and stromal compartments. In addition, we were able to determine the imprinting status of Igf2 in both compartments by examining embryos that had inherited the LacZDMR2 À allele uniparentally. Before e10.5, we could not detect reporter gene expression in either ependymal cells or in the underlying mesenchyme, following maternal or paternal transmission of LacZDMR2 À (not shown). At e10.5, paternal gene expression was detected in both the mesenchyme and in a subset of the overlying ependymal cells of the presumptive choroid plexus (Fig. 3a) . At the same stage, expression from the maternal allele was detectable only in the ependyma (Fig. 3b) . Subsequently, paternally derived gene expression was abundant in the developing stroma (Figs. 3d, g ), whereas the maternally derived reporter gene expression could not be detected in this region (Figs. 3e, h ). Gene expression from both parental alleles was detected in the choroid plexus epithelium. In contrast, H19 mRNA was detected in the stroma but not the epithelium of a wild-type embryo at e14.5 (Fig. 3j) , and was absent from both cell types in embryos with maternal transmission of an H19D3 knockout allele (Fig. 3k) . To confirm that Igf2 expression is associated with the choroid plexus, particularly at earlier stages when the characteristicfolded morphology of this organ has not been established, we have used an antibody that recognizes transthyretin (TTR). Within the brain, TTR expression was confined to the presumptive and definitive choroid plexus epithelium, with expression commencing at around e10.5 when the plexus epithelial cells differentiate from the neuroepithelium. This expression pattern is consistent with the previous description of TTR as a marker of choroid plexus epithelium (Murakami et al., 1987) . It is noted that TTR expression is uniform throughout the epithelium, in contrast with the variegated expression of Igf2 in this tissue.
We conclude that Igf2 is expressed in both the epithelial and stromal compartments of the choroid plexus from the onset of its development. Igf2 is imprinted (paternally expressed) in stromal cells, but biallelically expressed in the choroid plexus epithelium. H19 has a reciprocal expression pattern in the choroid plexus with expression from the maternally derived allele in the stroma and with both alleles silent in the epithelium. The CCD was thus able to drive reporter gene expression in a region where Igf2 is biallelically expressed, as predicted, but also in a region where the gene is imprinted.
P3-LacZ-CCD reporter transgenes are expressed in further tissues where Igf2 is imprinted
Further examination of CCD-bearing transgenics revealed gene expression in some additional embryonic tissues. The three high expressing lines (Columbo, Cornelius, and Christian) demonstrated reproducible patterns of gene expression in structures derived from the mesoderm and the neural crest (summarized in Table 1 ), as well as several line-specific sites of expression that are a presumed consequence of the transgene insertion sites (position effects).
At e9.5, all three lines showed staining in the mesenchyme at the site of the head fold, in the developing eye, and in the branchial arches. A subset of the condensing paraxial mesoderm was stained, as was the urogenital ridge (Fig. 4b) . By e10.5, a high level of staining was observed in the somites at their dorsolateral edge, in the mesenchyme surrounding the myencephalon including that which condenses to form the pia and arachnoid membranes of the leptomeninges (Rugh, 1990; Stylianpoulou et al., 1988a) , as well as in the mesenchyme surrounding the neural tube (Fig. 4c) . The mesonephros maintained expression of the reporter gene, and the developing eye was clearly stained. At e12.5 (Fig. 4f) , expression in the paraxial mesoderm had declined and was present only in the most posterior somites. Gene expression was wide- For each of the P3-LacZ-CCD transgenic lines, an estimation of transgene copy is given and also the number of embryos examined for expression of the LacZ reporter. Common sites of expression are those regions where the transgenes were expressed in the majority of lines. Position-dependent sites of expression were those unique to a transgenic line.
spread in the condensing ependyma of the brain and was present in the choroid plexus as it forms in the fourth ventricle. Cranial structures such as the eustachian tubules and semicircular canals of the ear, and the nasal mesenchyme and epithelium began to express the transgene at this stage, as did the intrinsic muscle of the tongue (Fig.  4e) . Expression was maintained in the mesonephros and in the eye (not shown). At e14.5, gene expression was lost from the derivatives of the somites. The tongue muscle, nasal epithelium and mesenchyme, ear and neck cartilage expressed the transgene (Fig. 4g) . The mesonephros has degenerated at this stage, but one of its derivatives, the ureter, displayed reporter gene expression (not shown).
The choroid plexus and meninges surrounding the brain and spinal cord continued to express the transgene, and we note that within the choroid plexus epithelium expression is restricted to a subset of cells, as is expression of endogenous Igf2 (see Fig. 3 ). After e14.5, gene expression declined in all tissues except the exchange tissues of the brain (Fig. 2c) . In summary, reproducible expression patterns were seen in three transgenic mouse lines containing the C construct, representing three independent integration events. This expression pattern represents a subset of the tissues in which Igf2 is expressed during mouse development (see Figs. 4a,  d) . Furthermore, in all the tissues described above (with the exception of the exchange tissues of the brain), the majority of Igf2 transcripts are generated from the paternal allele of the gene. The CCD is therefore acting as an enhancer both in tissues where Igf2 is imprinted and where it is biallelically expressed.
Discussion
We have established that Igf2 expression is biallelic from the earliest stages at which it can be detected (e10.5) in the presumptive choroid plexus epithelium. In contrast, imprinted (paternal-allele) expression is seen from the onset in choroid plexus stroma. We propose that this reflects the different origins of these two tissues (Catala, 1998; Davson, 1967) , and that epigenetic marks may be differently established in these lineages (see Fig. 5 ). Biallelic methylation of the differentially methylated regions proximal to Igf2 (DMR1 and DMR2) has been reported previously following analysis of whole choroid plexus, and the same report indicated that the H19 promoter exhibits only 50% methylation, consistent with differential allelic marking of this region (Feil et al., 1994) . The methylation status of the DMD in this tissue remains unknown, and no attempt has yet been made to separately analyze methylation in the stromal and epithelial compartments. However, it is possible that within the choroid plexus, biallelic methylation of Igf2 DMRs is restricted to the epithelium, and that this local hypermethylation is permissive for Igf2 expression.
The results of our transgenic experiments using the Igf2 P3-LacZ-CCD construct demonstrate that the CCD can act as a regional enhancer of a reporter gene during mouse devel- Fig. 4 . Expression of the C construct in tissues where Igf2 is imprinted. Representative embryos from the Columbo line are shown at e9.5 (b), e10.5 (c), e12.5 (e, f), and at e14.5 (g) with reference to Igf2 expression at e10 (a) and e12.5 (d). In the early embryo (a -c), the transgene is expressed in the head mesenchyme (me), in the branchial arches (ba), in a subset of the somitic mesoderm (so), and in the eye (ey). By e12.5 (d -f), this expression has become refined to the ependyma of the brain (me), the lens of the eye (ey), several regions of facial mesenchyme, to the posterior somites (dm), and the mesonephros (not shown). In later development (g), facial mesenchymal expression is resolved into specific areas including the tongue (to), the nasal epithelium (ne), and the ear (not shown).
opment in tissues where Igf2 is expressed both biallelically (the choroid plexus epithelium) and monoallelically (the stroma of the choroid plexus and also discrete sites outside of the brain). It is important to note that the Igf2 P3-LacZ-CCD transgenes did not exhibit any differences in expression when transmitted from either males or females, indicating that the isolated CCD is not sufficient to direct imprinted expression, a fact that is consistent with the absence from this region of any parental allele-specific methylation or DNaseI hypersensitivity (Koide et al., 1994) . The enhancer for choroid plexus expression has previously been predicted to lie within the interval between Igf2 and H19, both from transgenic experiments with CCD reporter constructs (Ward et al., 1997) , and from a 12 kb deletion, including the CCD, which showed reduced expression in the choroid plexus (Jones et al., 2001 ). The knockout study by Jones et al. (2001) did not report a reduction in levels of gene expression in any tissues other than the choroid plexus; however, the study measured gene expression quantitatively on dissected organs. Our study shows expression of the reporter gene in discrete tissues and developmental stages that could easily be missed by the previous approach. Likewise, deletion of the 5V 1 kb (including Region 1) of the CCD from a YAC transgene did not result in the loss of gene expression in any of the tissues that we report, and instead, CCD Region 1 was associated with a tissue-specific silencer function (Ainscough et al., 2000) . Consequently, we propose that the enhancer region most likely lies in the second 1 kb of the CCD that includes Region 2 (see Fig. 1 ). This must be confirmed by testing smaller reporter constructs to exclude alternative explanations, such as the presence of redundant enhancers that may have obscured the role of Region 1 in the YAC experiments. Within the choroid plexus epithelium, the CCD directed transgene expression in a mosaic fashion to only a subset of cells, mimicking the endogenous Igf2 expression pattern in this tissue. Interestingly, the silencer function of the mouse CCD was found to be conserved when it was tested in transgenic Drosophila and conferred variegated silencing on the mini-white reporter gene, with silencing dependent upon two polycomb-group proteins (Erhardt et al., 2003) . This suggests a mechanism by which enhancer and silencer elements within the CCD might interact to bring about variegated expression of Igf2 within the choroid plexus epithelium.
We propose that a mesodermal or neural crest enhancer element lies at the CCD, driving the imprinted expression of Igf2 independently of the Igf2/H19 boundary element. The Igf2 DMRs have been shown to play a role in the imprinting of Igf2 in the mesoderm (Constancia et al., 2000; Eden et al., 2001; Weber et al., 2001) . DMR1 contains several CpG dinucleotides that are hypomethylated on the maternally derived chromosome, and hypermethylated on the paternally derived chromosome (Brandeis et al., 1993; Feil et al., 1994; Sasaki et al., 1992) . Differences in the levels of methylation between parental chromosomes are most marked in tissues with a substantial mesodermal component (Weber et al., 2001) . A deletion encompassing DMR1, when maternally inherited, leads to a detectable derepression of the maternal Igf2 allele from e12 in whole embryos, and from e16 in individual mesodermal tissues (Constancia et al., 2000) . The authors suggest that DMR1 contains an allele-specific silencer that represses the maternal allele in the mesoderm. An additional methylation-sensitive silencer has been mapped within DMR1, but its action is not thought to be tissuespecific (Eden et al., 2001) . It would be of interest to ascertain if DMR1 can silence gene activity in the subset of mesodermal tissues stained in transgenic mice carrying the P3-LacZ-CCD reporter construct. The presence of enhancers located upstream of the DMD boundary, combined with Fig. 5 . Proposed model of Igf2 expression mediated by enhancer activity of the CCD. The Igf2 and H19 genes (gray boxes, not to scale) are shown relative to areas that may be differentially methylated between parental alleles [black boxes, from left to right Igf2 DMR1 and DMR2, the DMD (2 boxes) and H19 promoter-proximal region; black lollipops above the boxes indicates regions of methylation] and enhancers (shown as gray ovals, from left, CCD, endodermal enhancers and mesodermal enhancers). Curved arrows indicate interactions between enhancers and promoters. (a) In the choroid plexus epithelium, the CCD may drive Igf2 expression from the paternal allele and the maternal allele, as DMR1 methylation prevents the binding of Igf2-promoter silencing factors such as GCF. H19 is not expressed in the choroid plexus epithelium, perhaps due to the methylation of its promoter (though this has yet to be established; see text). (b) In other tissues where the CCD is active (i.e., CP stroma, somites, tongue, eye), the Igf2 promoter can be accessed on the paternal allele, due to methylation at DMR1. On the maternal allele, loss of DMR1 methylation allows the binding of silencing factors that prevent CCD enhancer activity. In addition, lack of methylation of the DMD on the maternal allele allows the binding of the boundary protein CTCF, and thus blocks the Igf2 promoter from access by the distal enhancers. differential methylation at Igf2 DMR1 and DMR2, could provide the basis of correct imprinted expression of Igf2 in some non-endodermal tissues, including the choroid plexus epithelium (see Fig. 5 ).
It has been shown recently that methylation of the DMRs at this locus is coordinated in a hierarchical fashion (Lopes et al., 2003) . Mutations in the DMD, when transmitted maternally, result in loss of differential methylation of both DMR1 and DMR2. Both alleles become highly methylated. Moreover, a maternally transmitted deletion encompassing DMR1 leads to a greater level of methylation of DMR2. Thus, cisacting elements are present in the DMD and upstream of Igf2 that act to protect the DMRs from methylation. This work confirms earlier experiments showing that Igf2-proximal DMR methylation is dependent upon DMD sequences (Forne et al., 1997) , but also highlights that perturbations of DMR1 could lead to the relaxation of Igf2 imprinting independently of the DMD. The DMRs proximal to Igf2 provide an additional level of imprinting control. In combination with enhancers proximal to the DMD boundary, these local DMRs may provide control of Igf2 imprinting that is independent of the DMD (Fig. 5) . We propose that such an enhancer region lies at the CCD and functions to drive imprinted expression of Igf2 in a small subset of tissues of mesodermal and neural crest origin. Other enhancer sequences may also lie within the interval between the Igf2 promoter and the DMD boundary (Drewell et al., 2002) . The presence of Igf2-proximal enhancers suggests that a distinct mechanism of Igf2 imprinting has arisen in two subsets of tissues where the gene is expressed. Mutations in this DMD-independent mechanism of Igf2 imprinting may account for some of the cases of Beckwith -Wiedemann syndrome, in which loss of imprinting of Igf2 occurs with no modification of methylation at the DMD (Engel et al., 2000) .
